Pharmaceuticals, Biotechnology and Life Sciences
Sareum Holdings, a drugmaker focused on cancer drugs on Monday announced cashing a $2.0 million milestone payment as part of the Chk1 licence agreement between its co-investment partner, the CRT Pioneer Fund, and Sierra Oncology, formerly known as ProNAi Therapeutics.
Clinigen Group has made a deal with Cumberland Pharmaceuticals to market another product in the US, this time an oncology drug Totect (dexrazoxane hydrochloride).
BMS and Janssen Biotech announced continuation of their work together through a new clinical research.
Celyad has started on Thursday its Therapeutic Immunotherapy with NKR-2 (THINK) trial in Belgium with the first patient giving blood.
To remind, THINK trial is an open-label Phase Ib study to assess the safety and clinical activity of multiple administrations of autologous CAR-T NKR-2 cells in seven refractory cancers.
Bayer has started off the new year with another approval from theU.S. Food and Drug Administration (FDA).
When her father’s lung cancer worsened, Yin Min, a 51-year-old financial broker from Shanghai, faced a choice: pay nearly $3,000 a month for an approved drug or pay a fraction of the price for a generic drug not approved for use in China.
Bristol-Myers Squibb Company and Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small molecule…
Bristol-Myers Squibb and PsiOxus Therapeutics have entered into an agreement granting Bristol-Myers Squibb exclusive worldwide rights to NG-348, a pre-clinical…
Confused about when to get your next Pap test? Anxious because your doctor said you don’t need another Pap for five years? Well, you are not alone.
Bayer on Monday announced the submission of applications to extend the marketing authorization for its oral multi-kinase inhibitor